# Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

> **NCT00460811** · PHASE2 · COMPLETED · sponsor: **Ironwood Pharmaceuticals, Inc.** · enrollment: 420 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Constipation

## Interventions

- **DRUG:** Linaclotide Acetate
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT00460811
- **Lead sponsor:** Ironwood Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-02
- **Final completion:** 2008-04
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2013-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460811, "Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00460811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*